Liposomes are considered the new drug delivery systems. These systems are defined as vesicular structures consisting of bilayers formed spontaneously when phospholipids are dispersed in water. Liposomes help in delivering drugs by the process of diffusion rather than by direct cell fusion. The global Liposome Drug Delivery market is projected to rise at a significant rate during the forecast period. Impacting factors such as an increase in the prevalence of cancer, which is mainly treated with liposome-encapsulated drugs, rise in applications of liposomes as drug delivery systems, its advantages, technological advances, and a strong pipeline of drugs are majorly contribute to the global Liposome Drug Delivery market expansion at a large extent.
Furthermore, several advantages are offered by liposome drug delivery, including the unique ability to entrap both hydrophilic and lipophilic compounds and allowing a varied range of drugs to be encapsulated by these vesicles. This fact further intensifies the growth of the global Liposome Drug Delivery market. In addition to this, applications of liposomes in drug delivery can be separated into diagnostic and therapeutic. These applications include anti-fungal, anti-cancer, and anti-inflammatory drugs. Major drugs formulated by employing liposome drug delivery include Doxil, AmBisome, and DepoDur. Therefore, an increase in applications of liposomes as drug delivery systems contributes more to the growth of the global Liposome Drug Delivery market.
Covid-19 Impact on Liposome Drug Delivery Market
In addition, the current Liposome Drug Delivery Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Liposome Drug Delivery Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Liposome Drug Delivery Market Segment Overview
Based on the Product, the Liposomal Doxorubicin is the prominent segment in the global Liposome Drug Delivery market. Doxorubicin (liposomal) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. It is the drug doxorubicin encapsulated in a closed lipid sphere (liposome). This medication is classified as an "anthracycline antibiotic." Doxorubicin (liposomal) is used to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Based on Application, the Cancer Therapy segment dominated the market and the trend is expected to continue throughout the forecast period. This can be mainly attributed to an increase in the prevalence of cancer and the strong pipeline of drugs focused on offering treatment for several types of cancer. According to World Health Organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
Liposome Drug Delivery Market, By Product
· Liposomal Doxorubicin
· Liposomal Paclitaxel
· Liposomal Amphotericin B
· Others
Liposome Drug Delivery Market, By Technology
· Stealth Liposome Technology
· Non-PEGylated Liposome Technology
· DepoFoam Liposome Technology
Liposome Drug Delivery Market, By Application
· Fungal Diseases
· Pain Management
· Cancer Therapy
· Viral Vaccines
· Photodynamic Therapy
Liposome Drug Delivery Regional Overview
In terms of region, North America dominated the global Liposome Drug Delivery market and is expected that the trend is continuing during the forecast period. Factors such as the presence of strong healthcare infrastructure, increasing cases of various types of cancer, and high expenditure and growing R&D activities in the medical sector are some key reasons escalating the growth of the market in this region. Similarly, the liposome drug delivery market in the Asia Pacific is estimated to expand at a high CAGR in the forecast periods. The growth of the market in the region can be primarily attributed to an increase in the number of patients suffering from chronic diseases and the focus of leading players on strengthening their presence in emerging markets.
Liposome Drug Delivery Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Liposome Drug Delivery Market, Key Players
· Spectrum Pharmaceuticals, Inc.
· Astellas Pharma, Inc.
· Gilead Sciences, Inc.
· Celsion Corporation
· Ipsen Pharma
· Pacira BioSciences, Inc.
· Luye Pharma Group
· Novartis AG
· Takeda Pharmaceutical Company Limited
· Johnson & Johnson
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Liposome Drug Delivery Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product
- 5.2.1. Liposomal Doxorubicin
- 5.2.2. Liposomal Paclitaxel
- 5.2.3. Liposomal Amphotericin B
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By Technology
- 5.3.1. Stealth Liposome Technology
- 5.3.2. Non-PEGylated Liposome Technology
- 5.3.3. DepoFoam Liposome Technology
- 5.4. Market Analysis, Insights and Forecast – By Application
- 5.4.1. Fungal Diseases
- 5.4.2. Pain Management
- 5.4.3. Cancer Therapy
- 5.4.4. Viral Vaccines
- 5.4.5. Photodynamic Therapy
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Liposome Drug Delivery Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product
- 6.2.1. Liposomal Doxorubicin
- 6.2.2. Liposomal Paclitaxel
- 6.2.3. Liposomal Amphotericin B
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast – By Technology
- 6.3.1. Stealth Liposome Technology
- 6.3.2. Non-PEGylated Liposome Technology
- 6.3.3. DepoFoam Liposome Technology
- 6.4. Market Analysis, Insights and Forecast – By Application
- 6.4.1. Fungal Diseases
- 6.4.2. Pain Management
- 6.4.3. Cancer Therapy
- 6.4.4. Viral Vaccines
- 6.4.5. Photodynamic Therapy
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Liposome Drug Delivery Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product
- 7.2.1. Liposomal Doxorubicin
- 7.2.2. Liposomal Paclitaxel
- 7.2.3. Liposomal Amphotericin B
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast – By Technology
- 7.3.1. Stealth Liposome Technology
- 7.3.2. Non-PEGylated Liposome Technology
- 7.3.3. DepoFoam Liposome Technology
- 7.4. Market Analysis, Insights and Forecast – By Application
- 7.4.1. Fungal Diseases
- 7.4.2. Pain Management
- 7.4.3. Cancer Therapy
- 7.4.4. Viral Vaccines
- 7.4.5. Photodynamic Therapy
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Liposome Drug Delivery Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product
- 8.2.1. Liposomal Doxorubicin
- 8.2.2. Liposomal Paclitaxel
- 8.2.3. Liposomal Amphotericin B
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast – By Technology
- 8.3.1. Stealth Liposome Technology
- 8.3.2. Non-PEGylated Liposome Technology
- 8.3.3. DepoFoam Liposome Technology
- 8.4. Market Analysis, Insights and Forecast – By Application
- 8.4.1. Fungal Diseases
- 8.4.2. Pain Management
- 8.4.3. Cancer Therapy
- 8.4.4. Viral Vaccines
- 8.4.5. Photodynamic Therapy
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Liposome Drug Delivery Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product
- 9.2.1. Liposomal Doxorubicin
- 9.2.2. Liposomal Paclitaxel
- 9.2.3. Liposomal Amphotericin B
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast – By Technology
- 9.3.1. Stealth Liposome Technology
- 9.3.2. Non-PEGylated Liposome Technology
- 9.3.3. DepoFoam Liposome Technology
- 9.4. Market Analysis, Insights and Forecast – By Application
- 9.4.1. Fungal Diseases
- 9.4.2. Pain Management
- 9.4.3. Cancer Therapy
- 9.4.4. Viral Vaccines
- 9.4.5. Photodynamic Therapy
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Spectrum Pharmaceuticals, Inc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Astellas Pharma, Inc.
- 10.6. Gilead Sciences, Inc.
- 10.7. Celsion Corporation
- 10.8. Ipsen Pharma
- 10.9. Pacira BioSciences, Inc.
- 10.10. Luye Pharma Group
- 10.11. Novartis AG
- 10.12. Takeda Pharmaceutical Company Limited
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
